Molecular Designs secures first FDA clearance for SimplicityDx Panel FluA/FluB/RSV assay
Molecular Designs, a physician-founded developer and manufacturer of molecular infectious disease assays, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K262789) for its SimplicityDx Panel FluA/FluB/RSV, the company's first FDA-cleared assay.
Read original article on The Medical News →Related news
-
Researchers trial AI coach for diabetes
United Kingdom
-
Optical imaging uncovers hidden movement map in the mouse brain
United Kingdom
-
Dyania and NVIDIA partner to scale AI-driven clinical reasoning across health systems
United Kingdom
-
CHLA researcher explores immune mechanisms behind rare pediatric neuroinflammatory diseases
United Kingdom
-
NIH funding advances research into overlooked organisms in the human gut
United Kingdom
-
Researchers discover bacterial molecule that rapidly repairs intestinal damage
United Kingdom
-
Study finds earlier endometrial cancer diagnoses among Native American and Hispanic women
United Kingdom
-
Common classroom accommodations fail to improve outcomes for children with ADHD
United Kingdom